Northwest Biotherapeutics, Inc. (NWBO)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Northwest Biotherapeutics, Inc. (NWBO) is down 16.2% since the beginning of the year. At $0 per share, NWBO is trading 47.9% below its 52-week high of $0. Investors who bought $1,000 worth of NWBO shares 5 years ago would now be looking at an investment worth $125.

Northwest Biotherapeutics, Inc. (NWBO) has returned -16.16% so far this year and -26.24% over the past 12 months. Over the last ten years, NWBO has returned -11.25% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.

Based on dividend-adjusted daily data since Dec 14, 2001, NWBO's average daily return is +0.34%, while the average monthly return is +2.52%. At this rate, an investment would double in approximately 2.3 years.

Historically, 40% of months were positive and 60% were negative. The best month was Feb 2005 with a return of +400.0%, while the worst month was Oct 2002 at -75.7%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 13 months.

On a daily basis, NWBO closed higher 37% of trading days. The best single day was Feb 2, 2005 with a return of +371.4%, while the worst single day was Apr 23, 2004 at -60.0%.

Northwest Biotherapeutics, Inc. has an annualized alpha of 127.60%, beta of 0.44, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since December 14, 2001.

• This stock participated in 184.84% of S&P 500 Index downside but only 16.35% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.44 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

NWBO ranks 23 for risk / return — below 23% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Northwest Biotherapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Northwest Biotherapeutics, Inc. was 99.99%, occurring on Jun 13, 2017. The portfolio has not yet recovered.

The current Northwest Biotherapeutics, Inc. drawdown is 99.99%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Northwest Biotherapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Northwest Biotherapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.